Smooth Muscle Cell Publications

  • Distinct phosphodiesterase-4D variants integrate into protein kinase A-based signaling complexes in cardiac and vascular myocytes. Raymond DR, Carter RL, Ward CA, Maurice DH. Am J Physiol Heart Circ Physiol. 2009 Feb;296(2):H263-71.
  • Formation of extracellular matrix-digesting invadopodia by primary aortic smooth muscle cells. Furmaniak-Kazmierczak E, Crawley SW, Carter RL, Maurice DH, Côté GP. Circ Res. 2007 May 11;100(9):1328-36.
  • Vascular smooth muscle cell phenotype-dependent phosphodiesterase 4D short form expression: role of differential histone acetylation on cAMP-regulated function. Tilley DG, Maurice DH. Mol Pharmacol. 2005 Sep;68(3):596-605.
  • Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo. Tilley DG, Maurice DH. Mol Pharmacol. 2002 Sep;62(3):497-506.
  • Reduced phosphodiesterase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle cells: implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues. Dunkerley HA, Tilley DG, Palmer D, Liu H, Jimmo SL, Maurice DH. Mol Pharmacol. 2002 May;61(5):1033-40.
  • Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease. Netherton SJ, Jimmo SL, Palmer D, Tilley DG, Dunkerley HA, Raymond DR, Russell JC, Absher PM, Sage EH, Vernon RB, Maurice DH. Diabetes. 2002 Apr;51(4):1194-200.
  • Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues. Palmer D, Maurice DH. Mol Pharmacol. 2000 Aug;58(2):247-52.
  • Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells. Liu H, Palmer D, Jimmo SL, Tilley DG, Dunkerley HA, Pang SC, Maurice DH. J Biol Chem. 2000 Aug 25;275(34):26615-24.
  • Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Liu H, Maurice DH. Br J Pharmacol. 1998 Dec;125(7):1501-10.
  • Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. Palmer D, Tsoi K, Maurice DH. Circ Res. 1998 May 4;82(8):852-61.
  • Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. Rose RJ, Liu H, Palmer D, Maurice DH. Br J Pharmacol. 1997 Sep;122(2):233-40.
  • Selective sequestration of nitric oxide by subcellular components of vascular smooth muscle and platelets: relationship to nitric oxide stimulation of the soluble guanylyl cyclase. Liu Z, Nakatsu K, Brien JF, Beaton ED, Marks GS, Maurice DH. Can J Physiol Pharmacol. 1993 Dec;71(12):938-45.
  • Measurement of both cyclic [3H]AMP and cyclic [3H]GMP in cultured vascular smooth muscle cells labeled with [3H]hypoxanthine: use in studies of cardiovascular drugs. Maurice DH, Lee RM, Haslam RJ. Anal Biochem. 1993 Nov 15;215(1):110-7.
  • Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle. Maurice DH, Crankshaw D, Haslam RJ. Eur J Pharmacol. 1991 Jan 10;192(2):235-42.
  • Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle. Maurice DH, Haslam RJ. Eur J Pharmacol. 1990 Dec 4;191(3):471-5.